FDA approves blood-based cancer test in medical breakthrough
Guardant Health's Shield blood test for colorectal cancer screening received FDA approval, potentially making it the first blood test eligible for Medicare coverage. The test, previously available as a lab-developed test for $895, detects 83% of colorectal cancers. Its approval targets over 50 million unscreened individuals, offering a more convenient alternative to stool-based tests.
Reference News
Guardant Health's Shield blood test for colorectal cancer screening received FDA approval, potentially making it the first blood test eligible for Medicare coverage. The test, previously available as a lab-developed test for $895, detects 83% of colorectal cancers. Its approval targets over 50 million unscreened individuals, offering a more convenient alternative to stool-based tests.